Ingredients6-Paradol is an aromatic phenolic ketone belonging to the vanilloid class of compounds. Its systematic (IUPAC) name is 1-(4-hydroxy-3-methoxyphenyl)-decan-3-one. Chemically, 6-paradol is a vanilloid derivative and is synthesized endogenously from 6-shogaol via a biotransformation process. Paradols are the olefin-reduced form of shogaols and are the major compounds of thermally processed ginger extract; they are also found in nature and thought to be biological metabolites of shogaols. As a member of the gingerol–shogaol–paradol homologous series, the "6-" prefix denotes a six-carbon alkyl side chain, distinguishing it from the structurally related 8-paradol and 10-paradol analogs within the same plant extracts.
Grains of Paradise (Aframomum melegueta K. Schum), also known as Alligator pepper or Guinea pepper, is a tropical plant from the genus Aframomum K. Schum of the ginger family Zingiberaceae. This plant is native to West Africa and is widely distributed across the tropical coastal regions of West and Central African countries. It is an herbaceous perennial plant that grows up to 1.5 m in height, with purple flowers that develop into 5–7 cm long pods containing small, reddish-brown aromatic and pungent seeds.
These genera are characterized by the presence of pungent principles such as gingerols, paradol, and shogaols. 6-Paradol is also detected in other Zingiberaceae plants such as Curcuma rhizomes and Alpinia officinarum rhizomes. Similar compounds are found in many species of the Zingiberaceae family including ginger (Zingiber officinale Roscoe), turmeric (Curcuma longa Linnaeus), and cardamom (Amomum cardamomum Linnaeus).
Grains of Paradise are very rich in the non-volatile pungent compounds gingerols, shogaols, paradols, and related compounds. By HPLC analysis, the most abundant compounds in a representative extract were putatively identified as [6]-gingerol (19.5% of the total extract), [6]-shogaol (12.5% of the total extract), and [6]-paradol (30.5% of the total extract, calculated as a percentage relative to total peak area at 254 nm). This places 6-paradol as the single most abundant of the three principal pungent constituents in standard seed extracts.
In dietary supplement applications, Aframomum melegueta seeds are typically prepared as ethanol-extracted concentrates and then standardized to a defined percentage of 6-paradol. The proprietary matrix of chemical components in branded Paradoxine® extract is referred to as 'Aframols,' and the extract is standardized to contain a minimum of 15% Aframols, with in particular 12.5% 6-paradol. The test article used in a 90-day oral toxicity study, CaloriBurn GP®, is an ethanol-extracted preparation derived from the seeds of Aframomum melegueta. A separate branded extract, AfperFIT™, is standardized to contain not less than 10% 6-paradol and has been used in recent human clinical work. The seeds are also available in whole, ground, or crude powder form as a culinary spice, though these forms are not standardized for 6-paradol content.
The herbaceous plant is part of the cultural identity and heritage of West Africa, where it is considered to have originated and has been used and cultivated for centuries, playing vital roles in traditional medicine, rituals, and ceremonies of various Indigenous cultures in the region and other parts of the world. In African folk medicine, Aframomum species are used for alleviating stomach ache and diarrhea as well as hypertension, as an aphrodisiac, and against measles and leprosy. They are also taken for excessive lactation and postpartum hemorrhage, and are used as a purgative, galactogogue, anthelmintic, and hemostatic agent.
Aframomum species have been traditionally used in African folk medicine for alleviating stomachache, diarrhea, fever, and hypertension. Moreover, it is used as an anti-inflammatory, aphrodisiac, laxative, and anthelmintic, and used to treat toothache, postpartum hemorrhage, measles, and leprosy. Aframomum melegueta (grains of paradise) is a herbaceous plant of West Africa locally used as a spice and to treat common ailments like diarrhea, painful arthritis, snake bite, and scorpion sting.
Portuguese sailors brought grains of paradise into Europe by the 13th century — before black pepper had fully dominated — and for a significant period it was one of the continent's most coveted spices. In 14th-century London, it could be found in apothecaries right next to cloves and cinnamon. It appears in ancient Arabic medical texts under the name "guinea grains," prized for its warming properties.
Later, the craze for the spice waned, and its uses were reduced to a flavoring for sausages and beer. In the 18th century, its importation to Great Britain collapsed after an act of Parliament during the reign of George III forbade its use in alcoholic beverages. A. melegueta is also cultivated in parts of Central and South America, the Caribbean, Southeast Asia, and some regions of Oceania.
In West African healing traditions, Aframomum melegueta was always more than a spice, playing a role in spiritual rituals, fertility rites, and was often incorporated into amulets for protection. These ritual dimensions of use, which are distinct from pharmacological applications, have been documented across multiple Indigenous cultures in the region.
Several phytochemical studies on A. melegueta have revealed the presence of alkaloids, diarylheptanoids, flavonoids, lignans, phenolics and polyphenolics, saponins, stilbenoids, terpenes, vanilloid compounds, as well as vitamins and minerals. The major pungent non-volatile constituents — gingerols, shogaols, and paradols — are the compounds most associated with biological activity.
The three primary peaks identified by LC-MS analysis are 6-gingerol, 6-shogaol, and 6-paradol. These compounds make up the bulk of the extract and were most likely responsible for the biological activity. Gingerols have reported blood glucose-lowering and anti-inflammatory activities, which may be useful for treating diabetes and cardiovascular disease.
6-Paradol is a non-pungent and biotransformed metabolite of 6-shogaol. It has been shown to exhibit a variety of biological activities including anti-cancer, anti-inflammatory, and anti-oxidative activities. Its structural relationship to capsaicin — the pungent compound in chili peppers — is notable; both belong to the broader vanilloid class. However, 6-paradol lacks the pungent character of capsaicin, making it more amenable to supplemental use without the sensory discomfort associated with capsaicinoids.
The most extensively investigated mechanism for 6-paradol is the stimulation of thermogenesis in brown adipose tissue (BAT). In a rat study, efferent discharges from sympathetic nerves entering the interscapular brown adipose tissue were recorded. Intragastric injection of a grains of paradise extract or 6-paradol enhanced the efferent discharges of the sympathetic nerves in a dose-dependent manner. The enhanced nerve discharges were sustained for as long as 3 hours, and the rats did not become desensitized to the stimulatory effects of these compounds on sympathetic nerve activity. The tissue temperature of brown adipose tissue showed significant increase in rats injected with 6-paradol. These results demonstrate that grains of paradise extracts and 6-paradol activate thermogenesis in brown adipose tissue.
Beyond direct BAT activation, 6-paradol-containing seed extracts have been shown to promote the "browning" of white adipose tissue (WAT). In high-fat diet-fed mice, six-week oral ingestion of a standardized A. melegueta seed extract significantly limited weight gain and improved brown adipose tissue activity. Notably, the extract markedly induced the formation of beige adipocytes in epididymal white adipose tissue (eWAT). Treatment led to the upregulation of the marker proteins uncoupling protein 1 (UCP1), peroxisome proliferator-activated receptor-gamma-coactivator 1-alpha (PGC-1α), and peroxisome proliferator-activated receptor gamma (PPARγ) in both eWAT and BAT.
Among tested ginger-derived compounds, 6-paradol and 6-shogaol showed potent activity in stimulating glucose utilization by 3T3-L1 adipocytes and C2C12 myotubes. These effects were attributed to the increase in 5′ adenosine monophosphate-activated protein kinase (AMPK) phosphorylation in 3T3-L1 adipocytes. 6-Paradol, the major metabolite of 6-shogaol, was utilized in an in vivo assay and significantly reduced blood glucose, cholesterol, and body weight in high-fat diet-fed mice.
However, the relationship between 6-paradol and AMPK is not entirely straightforward. A 2021 study found that 6-paradol decreased body weight gain and visceral and subcutaneous fats in two weeks in high-fat diet-fed obese mice, whereas 6-gingerol and 6-shogaol had no effect. Additionally, 6-paradol suppressed hepatic cholesterol and triglyceride and significantly decreased the gene expression related to fatty acid synthesis, lipid transportation, and adipogenesis. The results suggest that 6-paradol regulates several obesity-related genes in an AMPK-independent manner, indicating it could be the principal active vanilloid in grains of paradise with anti-obesity properties acting through a different mechanism.
The active compounds in grains of paradise, such as gingerols, paradols, and shogaols, are considered to be the main sources of its pharmacological activities, partially achieved by inhibiting the activity of COX-2 enzyme and the expression of pro-inflammatory genes. Pretreatment with 6-paradol reduced neuroinflammatory responses in LPS-stimulated BV2 microglia in a concentration-dependent manner, including reduced nitric oxide (NO) production by inhibiting iNOS upregulation and lowered secretion of pro-inflammatory cytokines (IL-6 and TNF-α).
6-Paradol was shown in a rat model to upregulate the Nrf2 pathway via enhancing Nrf2 mRNA expression and heme oxygenase-1 (HO-1) levels, suppress renal NF-κB mRNA expression and NLRP3 inflammasome pathway expression, and enhance renal autophagy through upregulating LC3B, AMPK, and SIRT-1, while suppressing mTOR, p-AKT mRNA expressions, and phosphorylated-p62 levels.
6-Paradol has a plethora of pharmacological actions including antioxidant, anti-inflammatory, and anti-bacterial activities. Further, it has been shown to possess neuroprotective, anti-obesity, and anti-ulcerative colitis actions, as well as having the potential to alleviate diabetic neuropathy. In the context of benign prostatic hyperplasia research, inhibition of the AKT/mTOR signaling axis has been identified as a contributing mechanism. Male Wistar rats treated daily with 6-paradol at doses of 2.5 and 5.0 mg/kg (alongside testosterone) showed significant amelioration of the testosterone-induced rise in prostate index and weight.
A rat study aimed to explore the thermogenic effects of grains of paradise extracts and of 6-paradol specifically. Efferent discharges from sympathetic nerves entering the interscapular brown adipose tissue were recorded. Intragastric injection of the extract or 6-paradol enhanced the efferent discharges of the sympathetic nerves in a dose-dependent manner. This provides mechanistic evidence for sympathetically mediated BAT activation. A two-week oral administration of 6-paradol significantly reduced the visceral and subcutaneous fat depots in male mice, while this effect was not observed with 6-gingerol or 6-shogaol, supporting 6-paradol as the active anti-obesity vanilloid within the grains of paradise complex.
The most cited early human study on grains of paradise extract was a 2013 single-blind, randomized, placebo-controlled, crossover trial. A total of nineteen healthy male volunteers aged 20–32 years underwent FDG-PET after 2 hours of cold exposure at 19°C. Twelve subjects showed marked FDG uptake into the adipose tissue of the supraclavicular and paraspinal regions (BAT positive), and the remaining seven showed no detectable uptake (BAT negative). Within four weeks after FDG-PET examination, whole-body energy expenditure was measured at 27°C before and after oral ingestion of grains of paradise extract (40 mg) in a single-blind, randomized, placebo-controlled, crossover design. This study, published in the British Journal of Nutrition, established that a single oral dose of the extract increased energy expenditure selectively in BAT-positive individuals, suggesting that BAT activity is a prerequisite for the thermogenic response.
A 2014 follow-up study addressed daily ingestion over four weeks. The study aimed to examine daily ingestion of grains of paradise extract on whole-body energy expenditure and body fat in humans. Whole-body energy expenditure and body fat content were measured before and after daily oral ingestion of grains of paradise extract at 30 mg/d for four weeks in 19 non-obese female volunteers aged 20–22 years, in a single-blind, randomized, placebo-controlled, crossover design. Four-week daily ingestion of the extract decreased visceral fat area at the umbilicus level, while the placebo group showed a slight increase. The daily ingestion of grains of paradise, but not the placebo, increased whole-body energy expenditure. The results suggest that grains of paradise extract may be an effective and safe tool for reducing body fat, mainly by preventing visceral fat accumulation. This study was published in the Journal of Nutritional Science and Vitaminology.
A more recent double-blind, placebo-controlled trial used a standardized extract (AfperFit) with confirmed 6-paradol content. In a double-blind, placebo-controlled clinical trial design, researchers examined the thermogenic effects of a standardized A. melegueta seed extract (AfperFit). A total of 70 overweight male and female subjects (BMI ≥25.0 to ≤30.0 kg/m²) aged 20–50 years were enrolled and administered with either 250 mg of AfperFit or placebo in capsule form twice daily for 12 weeks. A previous clinical trial demonstrated that 12 weeks of A. melegueta seed extract intake increased energy expenditure through the activation of brown adipose tissue (BAT) and a decrease in fat reduction.
A 2021 study, referenced in the Cochrane Library, investigated prolonged treatment: prolonged treatment with grains of paradise extract was found to recruit adaptive thermogenesis and reduce body fat in humans with low brown fat activity, extending the population of potential responders beyond those with high baseline BAT activity.
The human evidence base for thermogenic and body composition effects is preliminary to moderate. The available trials are small (19–70 subjects), short-term (4–12 weeks), and several lack full double-blinding. Industry affiliation of some study authors is a noted limitation. No large-scale, independent, multi-center randomized controlled trials or systematic reviews with meta-analysis have been published as of the time of writing. Effects appear most reliably demonstrated in individuals with detectable BAT activity. The animal mechanistic data is consistent and multi-laboratory, strengthening biological plausibility.
Researchers prepared 10 ginger active components (6-, 8-, 10-paradols, 6-, 8-, 10-shogaols, 6-, 8-, 10-gingerols, and zingerone) and evaluated their anti-hyperglycemic activity. Among the tested compounds, 6-paradol and 6-shogaol showed potent activity in stimulating glucose utilization by 3T3-L1 adipocytes and C2C12 myotubes. The effects were attributed to the increase in AMPK phosphorylation in 3T3-L1 adipocytes. A toxicological study demonstrated that a grains of paradise extract rich in 6-gingerol, 6-shogaol, and 6-paradol is capable of decreasing blood glucose, but at higher doses may cause liver toxicity.
Grains of paradise has been found to have hypoglycemic effects, positioning it as a potential candidate for the treatment of diabetes.
All available evidence for glucose regulation is preclinical (in vitro and animal). No human clinical trials specifically examining 6-paradol or grains of paradise extract for glycemic control in diabetic or pre-diabetic populations have been identified in the published literature. This area requires dedicated human study before clinical conclusions can be drawn.
The pharmacological activities of the active compounds in grains of paradise are partially achieved by inhibiting the activity of COX-2 enzyme and the expression of pro-inflammatory genes. In activated microglia, a robust increase in NO production and pro-inflammatory cytokines (IL-6 and TNF-α) was markedly blocked by exposure to 6-paradol, indicating that it may function as a neuroprotectant that reduces inflammatory responses. These in vitro neuroprotective effects were reaffirmed in an animal model of cerebral ischemia where 6-paradol showed therapeutic benefits by reducing microglial activation and TNF-α expression.
Several phytochemical studies on A. melegueta have revealed the presence of vanilloid compounds and other phytochemicals, and the crude extracts, fractions, and purified compounds possess biological activities including anti-inflammatory and antioxidant properties, some of which have been shown to have therapeutic relevance.
Anti-inflammatory evidence is predominantly in vitro and animal-based. While the COX-2 inhibition and cytokine suppression findings are mechanistically credible and consistent across multiple laboratories, no human clinical trials have evaluated 6-paradol's anti-inflammatory effects as a primary endpoint.
Paradol, described as a non-pungent metabolite of shogaol by enzymatic reduction, is known to possess anti-inflammatory activities. Current in vitro findings demonstrate that the inhibitory properties of 6-paradol in treating neuroinflammation in microglia correlate to in vivo therapeutic potential for cerebral ischemia. This study provides evidence of 6-paradol's neuroprotective efficacy in cerebral ischemia and indicates its potential use in the treatment of other CNS disorders in which neuroinflammation is a pathological feature. This study also explains the mechanism of action of 6-shogaol in diverse CNS disorders as it relates to the biotransformation of 6-shogaol.
Previous studies have reported that 6-shogaol, a major constituent of ginger, and its biological metabolite, 6-paradol, have anti-inflammatory and anti-oxidative properties in the central nervous system. In one study, researchers investigated whether 6-shogaol and 6-paradol could ameliorate experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis elicited by myelin oligodendrocyte glycoprotein peptide immunization. Neuroprotective effects of ginger extract appear to be due to pharmacological actions of both 6-shogaol and 6-paradol because they exert anti-neuroinflammatory and anti-oxidative activities in the CNS.
One study was designed to investigate the biotransformation of 6-shogaol to 6-paradol from 6-shogaol-enriched ginger extracts by fermentation using Schizosaccharomyces pombe and evaluate the neuroprotective effect of the resulting extract. During fermentation, 6-gingerol content was maintained while 6-shogaol was efficiently biotransformed to 6-paradol. The fermented ginger extract was evaluated for neuroprotective effect against amyloid-beta (Aβ)-induced neurotoxicity in rat primary hippocampal cells.
Neuroprotective evidence is in vitro and animal only. Findings in models of focal cerebral ischemia, multiple sclerosis (EAE), and Alzheimer's-related amyloid-beta toxicity are mechanistically interesting and internally consistent, but no human clinical studies have been conducted. Translation to clinical outcomes remains unestablished.
Topical application of [6]-paradol and its derivatives inhibited TPA-induced ear edema, hydrogen peroxide production, and myeloperoxidase activity in the dorsal skin of mice. Induction of TPA-induced mouse epidermal ornithine decarboxylase (ODC) activity and Hâ‚‚Oâ‚‚- and UV-induced formation of oxidized DNA bases in vitro were also attenuated. These results indicate that [6]-paradol and its derivatives possess cancer chemopreventive potential.
A hamster buccal pouch carcinogenesis study provided additional in vivo evidence. The mechanistic pathway for the chemopreventive potential of 6-paradol was evaluated by measuring the status of tumor incidence, volume, and burden, as well as the status of phase II detoxification agents, lipid peroxidation, and antioxidants. Oral squamous cell carcinoma was induced in hamster buccal pouches by painting them with 0.5% DMBA in liquid paraffin three times a week for 14 weeks. 100% tumor formation with marked biochemical abnormalities was observed in tumor-bearing animals compared to control animals.
Chemopreventive evidence is entirely preclinical — confined to cell culture models and animal carcinogenesis studies. The data support a mechanistic basis for further investigation but do not constitute clinical evidence of anti-cancer effects in humans.
Effects of individual active constituents from the Zingiberaceae family on ulcerative colitis and other inflammatory models have been investigated; however, no study had previously been conducted specifically with paradol until recent animal work. A study was therefore designed to explore the protective effect of 6-paradol in acetic acid-induced ulcerative colitis in rats. Anti-inflammatory, antioxidant, gastroprotective, immunomodulatory, antinociceptive, antimicrobial, antidiabetic, and anticancer activities have been reported from the extract of A. melegueta and its active components. Previous reports advocate anticancer, anti-diabetic, antioxidant, anti-inflammatory, and immunomodulatory activities of 6-paradol, which is one of the major constituents of grains of paradise.
Evidence for gastrointestinal protection is animal model only. The traditional use of the plant for stomachache and diarrhea is ethnographically documented, but controlled human evidence is lacking.
Researchers investigated the protective effects of 6-Paradol (PDL) against diclofenac-induced acute kidney injury, with focus on renal autophagy and NLRP3 inflammasome pathways. PDL has anti-inflammatory, antioxidant, and AMPK-activation properties. Compared to diclofenac alone, PDL restored serum nephrotoxicity markers, renal oxidative stress, and pro-inflammatory markers. PDL almost restored renal architecture, upregulated the Nrf2 pathway, suppressed renal NF-κB mRNA expression and NLRP3 inflammasome pathway expression, and enhanced renal autophagy through upregulating LC3B, AMPK, and SIRT-1.
Nephroprotective evidence is animal model only. No human clinical data exist. The mechanistic pathways implicated (Nrf2/NLRP3/AMPK) are biologically relevant but require clinical validation.
6-Paradol (6-PD) is an active metabolite found in many members of the Zingiberaceae family. It was reported to possess anti-proliferative, antioxidant, and anti-inflammatory activities. One study aimed at exploring the potential of 6-PD to inhibit testosterone-induced benign prostatic hyperplasia (BPH) in rats. Male Wistar rats were divided into groups and treated with 6-PD at 2.5 and 5.0 mg/kg (alongside testosterone), alongside a finasteride-positive control group. Daily treatment of animals with 6-PD at both dose levels significantly ameliorated the testosterone-induced rise in prostate index and weight.
Evidence is limited to a single animal model study. No human clinical data for BPH or prostate health are available. The results are hypothesis-generating.
One study assessed the antiviral activity of ethanolic extracts from commercial samples of Aframomum melegueta seeds using XTT cytotoxicity assays and cell-based models for SARS-CoV-1 and SARS-CoV-2. Chromatographic analysis identified fifteen gingerols, with 6-gingerol being the most prevalent. The extracts showed selective antiviral activity with therapeutic index (TI) values up to 13.1. Antibacterial properties have also been attributed to 6-paradol-containing preparations, though the majority of this work has been conducted in vitro.
6-Paradol is not commercially available as an isolated pure compound for supplemental use. It is consumed as a component of standardized extracts of Aframomum melegueta seeds. The following dosages have been reported in the primary scientific literature:
The branded extract Paradoxine® contains a proprietary matrix referred to as Aframols and is standardized to contain a minimum of 15% Aframols, with 12.5% 6-paradol specifically. Therefore, a 100 mg capsule of Paradoxine® provides approximately 12.5 mg of 6-paradol. No regulatory body has established an official dietary reference intake or tolerable upper intake level for 6-paradol or grains of paradise extract.
A formal toxicological study demonstrated that a grains of paradise extract rich in 6-gingerol, 6-shogaol, and 6-paradol is capable of decreasing blood glucose, but at higher doses may cause liver toxicity. Beyond liver enlargement and elevation in alkaline phosphatase, there were few dose-related changes observed in the study. These findings were from a rodent study and used doses substantially above those employed in human supplementation studies.
Despite promising therapeutic findings, the toxicological profile of grains of paradise is not fully elucidated. A 90-day OECD 408-compliant toxicology study was conducted to provide a comprehensive evaluation of safety following extended administration. By examining the chronic effects on various physiological systems, the study aimed to determine the No Observed Adverse Effect Level (NOAEL) and identify any potential long-term toxicological risks associated with the consumption of grains of paradise extract.
In the human trials published to date, grains of paradise extract has been reported to be well tolerated. No serious adverse events were noted in the 40 mg acute dose study (19 men), the 30 mg/day 4-week study (19 women), or the 500 mg/day 12-week study (70 overweight adults). Grains of paradise is generally considered safe, but long-term effects are not well-studied. Common side effects are not well-documented but may include gastrointestinal upset.
The extract has been demonstrated to be capable of decreasing blood glucose. This hypoglycemic effect, documented in animal studies, implies a potential interaction with antidiabetic medications. Individuals receiving insulin or oral hypoglycemic agents should be aware of the possibility of additive glucose-lowering effects, although this has not been directly studied in humans.
The animal toxicology data flagged liver enlargement and elevated alkaline phosphatase at higher extract doses. The grains of paradise extract rich in 6-gingerol, 6-shogaol, and 6-paradol may cause liver toxicity at higher doses, though beyond liver enlargement and elevation in alkaline phosphatase, there were few other dose-related changes. The relevance of these rodent findings to human supplementation at typical doses (30–500 mg extract/day) has not been directly evaluated.
Similar compounds to those in grains of paradise are found in many species of the Zingiberaceae family including ginger, turmeric, and cardamom. Individuals with known hypersensitivity to members of the ginger family should consider this botanical relationship when evaluating tolerability.
Research on grains of paradise is considered moderate, with several human trials supporting its benefits, although more systematic reviews are needed for a comprehensive understanding. The long-term safety profile beyond 12 weeks of supplementation in humans has not been formally assessed in published independent studies. No pharmacokinetic data specifically characterizing the absorption, distribution, metabolism, and excretion (ADME) of isolated 6-paradol in humans have been identified in the peer-reviewed literature as of the time of writing.
Health conditions that 6-paradol may help support.
6-Paradol is the primary thermogenic compound in grains of paradise (Aframomum melegueta). It directly triggers brown adipose tissue thermogenesis by stimulating sympathetic nerve efferent discharges dose-dependently, with sustained effects up to 3 hours and no desensitization. Published in Autonomic Neuroscience (2010) and confirmed in human FDG-PET BAT activation studies.
Body systems that 6-paradol may help support.
Go back